QuPath statistics

info info

Citations per year

Number of citations per year for the bioinformatics software tool QuPath

Tool usage distribution map

info info

Associated diseases


Popular tool citations

chevron_left Morphometric analysis Cell counting Data analysis Image visualization Image classification chevron_right
Want to access the full stats & trends on this tool?

QuPath specifications


Unique identifier OMICS_14868
Name QuPath
Software type Package/Module
Interface Graphical user interface
Restrictions to use None
Operating system Unix/Linux
License GNU General Public License version 3.0
Computer skills Medium
Stability Stable
Maintained Yes




No version available



  • person_outline Peter Hamilton

Publication for QuPath

QuPath citations


Bcl xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF mutant stage II and III colon cancer

PMCID: 5862619
PMID: 29568398
DOI: 10.18632/oncotarget.24481

[…] ASMT n = 248, WT/WT n = 321). Using the IHC methodology optimized in line with the REMARK guidelines in whole face CC sections, we assessed Bcl-xL protein expression using digital pathology software, QuPath [], to give a numerical representation of both the extent and the intensity of staining (H-score), based on the mean expression of all cores (3 cores for each patient). In line with REMARK guid […]


Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population Based Cohort Study

PMCID: 5543466
PMID: 28448072
DOI: 10.1038/ctg.2017.18

[…] platform using an OptiView antibody detection system (Ventana Medical Systems Inc., Tucson, USA) and a Cell Marque ready to use rabbit monoclonal antibody to PTGS2 (Ventana, catalog number 760-4254). QuPath (Queen’s University Belfast, Northern Ireland) image analysis software facilitated digital immunoscoring. More detailed information is provided in the (online). A H-score was calculated based […]

Want to access the full list of citations?
QuPath institution(s)
Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, UK; Tissue Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK; Centre for Experimental Medicine, Queen’s University Belfast, Belfast, Northern Ireland, UK; Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
QuPath funding source(s)
Supported by Invest Northern Ireland (RDO0712612); Cancer Research UK Accelerator (C11512/A20256); by Cancer Research UK, Experimental Cancer Medicine Centre Network, the NI Health and Social Care Research and Development Division, the Sean Crummey Memorial Fund, the Tom Simms Memorial Fund and the Friends of the Cancer Centre; by the Health and Social Care Research and Development Division of the Public Health Agency in Northern Ireland and Cancer Research UK (ref. SPI/5069/14); the Friends of the Cancer Centre by Cancer Research UK (ref. C37703/A15333 and ref. C50104/A17592) and the HSC R&D office of Northern Ireland (ref. EAT/4905/13) and by the NI Public Health Agency.

QuPath reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review QuPath